Is Charcot-Marie-Tooth Disease Autoimmune?
At a Glance
Charcot-Marie-Tooth disease (CMT) is not an autoimmune disease. It is an inherited genetic disorder that damages the peripheral nerves. While it shares symptoms with autoimmune conditions like CIDP, CMT requires completely different management, such as physical therapy and bracing, rather than immune-suppressing medications.
In this answer
2 sections
No, Charcot-Marie-Tooth disease (CMT) is not an autoimmune disease [1][2][3]. It is an inherited, genetic disorder that affects the peripheral nerves (the nerves outside the brain and spinal cord that control muscles and sensation) [4]. In an autoimmune disease, the body’s immune system mistakenly attacks its own healthy tissues [5]. In CMT, the damage to the nerves is caused by inherited genetic mutations, not by an immune system attack [4][3].
Why CMT is Often Confused with Autoimmune Disorders
It is very common for patients to wonder if CMT is an autoimmune condition because it shares many symptoms with autoimmune neuropathies, particularly a condition called CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) [4][6]. Both conditions can cause muscle weakness, numbness, and loss of reflexes, and both involve damage to the peripheral nerves [7].
However, the underlying mechanisms are completely different:
- CMT is genetic: It is caused by changes (mutations) in your DNA that affect the proteins needed to build and maintain the structure of your nerves or the myelin (the protective coating around your nerves) [8][4]. You are born with these genetic changes, even though symptoms may not become noticeable until later in life [3].
- CIDP is autoimmune (acquired): In CIDP, a person’s immune system creates inflammation and actively attacks their healthy myelin [5][9].
Why Autoimmune Treatments Don’t Work for CMT
Because CMT and autoimmune neuropathies have different causes, they require entirely different approaches to management.
Autoimmune conditions like CIDP are treated with therapies that suppress or modulate the immune system, such as corticosteroids, immunosuppressants, or intravenous immunoglobulin (IVIG) [4][6]. These treatments work by calming the immune system to stop the inflammatory attack on the nerves [10][11].
Because the immune system is not attacking the nerves in CMT, these immune-suppressing treatments are generally ineffective for treating it [6][10]. Taking immunosuppressants for CMT (if it is misdiagnosed as an autoimmune condition) is not only ineffective but can expose a person to unnecessary medication side effects [4][6]. Using steroids or IVIG will not repair the genetic structural deficits in the nerves [4][6].
Instead, managing CMT focuses on physical therapy, supportive devices (like braces), occupational therapy, genetic counseling to understand family risks, and in some cases, surgery to address the structural changes caused by the neuropathy.
(Note: There are very rare cases where a person might have both an inherited genetic neuropathy and a secondary inflammatory component, but the primary cause of CMT remains genetic [12][13].)
Common questions in this guide
Is Charcot-Marie-Tooth disease an autoimmune disorder?
Why is CMT often confused with autoimmune diseases?
Do autoimmune treatments like steroids or IVIG work for CMT?
How is Charcot-Marie-Tooth disease treated?
How can I tell the difference between CMT and an autoimmune neuropathy?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Have we definitively ruled out acquired autoimmune neuropathies like CIDP through genetic testing or other diagnostics?
- 2.Would I benefit from seeing a genetic counselor to understand my specific mutation and what it means for my family members?
- 3.If my symptoms suddenly get much worse, could that indicate an inflammatory issue in addition to CMT, and when should I contact you?
- 4.What are the most effective daily management strategies (like physical therapy or bracing) for my specific type of CMT?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (13)
- 1
Charcot-Marie-Tooth Disease and Other Hereditary Neuropathies.
Klein CJ
Continuum (Minneapolis, Minn.) 2020; (26(5)):1224-1256 doi:10.1212/CON.0000000000000927.
PMID: 33003000 - 2
Hearing loss in inherited peripheral neuropathies: Molecular diagnosis by NGS in a French series.
Lerat J, Magdelaine C, Roux AF, et al.
Molecular genetics & genomic medicine 2019; (7(9)):e839 doi:10.1002/mgg3.839.
PMID: 31393079 - 3
On the path to evidence-based therapy in neuromuscular disorders.
Younger DS
Handbook of clinical neurology 2023; (195()):315-358 doi:10.1016/B978-0-323-98818-6.00007-8.
PMID: 37562877 - 4
Charcot-Marie-Tooth disease misdiagnosed as chronic inflammatory demyelinating polyradiculoneuropathy: An international multicentric retrospective study.
Hauw F, Fargeot G, Adams D, et al.
European journal of neurology 2021; (28(9)):2846-2854 doi:10.1111/ene.14950.
PMID: 34060689 - 5
Immune-mediated neuropathies.
Kieseier BC, Mathey EK, Sommer C, Hartung HP
Nature reviews. Disease primers 2018; (4(1)):31 doi:10.1038/s41572-018-0027-2.
PMID: 30310069 - 6
Repeated clear benefits of immunotherapy in a patient with Charcot-Marie-Tooth disease carrying a rare point mutation in PMP22.
Kawai H, Nishida Y, Kanda T, Yokota T
Neurogenetics 2025; (26(1)):37 doi:10.1007/s10048-025-00808-9.
PMID: 40126701 - 7
Elderly patients with suspected Charcot-Marie-Tooth disease should be tested for the TTR gene for effective treatments.
Taniguchi T, Ando M, Okamoto Y, et al.
Journal of human genetics 2022; (67(6)):353-362 doi:10.1038/s10038-021-01005-w.
PMID: 35027655 - 8
De novo PMP2 mutations in families with type 1 Charcot-Marie-Tooth disease.
Motley WW, Palaima P, Yum SW, et al.
Brain : a journal of neurology 2016; (139(Pt 6)):1649-56 doi:10.1093/brain/aww055.
PMID: 27009151 - 9
Complement profiling of sural nerves in chronic-inflammatory demyelinating polyneuropathy.
Stascheit F, Roos A, Schroeter CB, et al.
Acta neuropathologica 2025; (150(1)):32 doi:10.1007/s00401-025-02936-w.
PMID: 40971018 - 10
Randomized, controlled crossover study of IVIg for demyelinating polyneuropathy and diabetes.
Breiner A, Barnett Tapia C, Lovblom LE, et al.
Neurology(R) neuroimmunology & neuroinflammation 2019; (6(5)) doi:10.1212/NXI.0000000000000586.
PMID: 31454771 - 11
Aberrant Complement Activation Is a Prominent Feature of Chronic Inflammatory Demyelinating Polyneuropathy.
Stascheit F, Preßler H, Stein K, et al.
Neurology(R) neuroimmunology & neuroinflammation 2026; (13(2)):e200542 doi:10.1212/NXI.0000000000200542.
PMID: 41499725 - 12
[Phenotypes of Charcot-Marie-Tooth Syndrome and Differential Diagnosis Focused in Inflammatory Neuropathies].
Iijima M
Brain and nerve = Shinkei kenkyu no shinpo 2016; (68(1)):31-42 doi:10.11477/mf.1416200343.
PMID: 26764297 - 13
Rapidly Progressive Polyneuropathy in a Patient With Monoclonal Gammopathy: A Case Report of POEMS Syndrome and Beyond.
Wang C, Guan YZ, Cai QQ, et al.
Medicine 2016; (95(16)):e3453 doi:10.1097/MD.0000000000003453.
PMID: 27100445
This page is for informational purposes only and does not replace professional medical advice. Always consult your neurologist or healthcare provider for an accurate diagnosis and treatment plan tailored to your condition.
Get notified when new evidence is published on Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.